skip to main content
Idioma:
Refinado por: Base de dados/Biblioteca: Elsevier SD Cell Press remover tipo de recurso: Anais de Congresso remover ScienceDirect (Online service) remover
Result Number Material Type Add to My Shelf Action Record Details and Options
1
iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody Represent a Novel Therapeutic Strategy to Avoid Host Immune Cell Rejection for Off-the-Shelf Cell-Based Cancer Immunotherapy
iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody Represent a Novel Therapeutic Strategy to Avoid Host Immune Cell Rejection for Off-the-Shelf Cell-Based Cancer Immunotherapy
Material Type:
Ata de Congresso 		Adicionar ao Meu Espaço

iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody Represent a Novel Therapeutic Strategy to Avoid Host Immune Cell Rejection for Off-the-Shelf Cell-Based Cancer Immunotherapy

Williams, AM ; Mbofung, RM ; Karimi, M ; Hayama, K ; Pan, YJ ; Groff, B ; Dailey, T ; Meza, M ; Mahmood, S ; Mathavan, K ; Bonello, G ; Lee, T ; Hammer, Q ; Malmberg, KJ ; Szabo, PM ; Wong, L ; Cooley, S ; Bjordahl, R ; Goodridge, J ; Valamehr, B

MOLECULAR THERAPY, 2022, Vol.30 (4), p.314 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Personalize Seus Resultados

  1. Editar

Refine Search Results

Expandir Meus Resultados

  1.   

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.